drugset / Trial / NCT04376827
A Study of Guselkumab in Participants With Active Lupus Nephritis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy of guselkumab in participants with active lupus nephritis (LN).
Timeline
- Start
- 2020-09-15
- Primary completion
- 2023-02-01
- Completion
- 2023-02-01
Publications
- Anders HJ, Chan TM, Sanchez-Guerrero J, Wofsy D, Bensley K, Kim L, Lo KH, Shu C, Shao J, Karyekar CS, Diamond B. Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study. Rheumatology (Oxford). 2025 May 1;64(5):2731-2740. doi: 10.1093/rheumatology/keae647.
- Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of Lupus Nephritis: New Treatments and Updated Guidelines. Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guselkumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Guselkumab | Monoclonal antibody | 400 mg | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | — | — |
| Background | mycophenolic acid | Small molecule | — | — |